Literature DB >> 24914324

Optimal treatment strategy for Helicobacter pylori: era of antibiotic resistance.

Jun Heo1, Seong Woo Jeon1.   

Abstract

Standard triple therapy, consisting of a proton pump inhibitor, plus amoxicillin and clarithromycin, has been the most commonly used first-line treatment regimen for Helicobacter pylori (H. pylori) eradication for many years worldwide. However, as a result of increased resistance to antibiotics, H. pylori eradication rates with use of standard triple therapy have been declining and recently reached < 80% in many countries. Several new strategies to enhance the eradication rate of H. pylori have been studied. Currently, among the alternative first-line eradication regimens, concomitant and hybrid regimens have shown excellent results and could be the optimal treatment option. Although clinical usefulness of rescue therapy for patients in whom eradication of H. pylori with non-bismuth quadruple regimen has failed is unclear, levofloxacin-based quadruple therapy has shown promise as a rescue treatment. The choice of third-line therapy depends on factors such as the local pattern of antibiotic resistance, drug availability, and previous treatment. We hope that a simple method for detection of antibiotic susceptibility using polymerase chain reaction would be a possible alternative to administration of "tailored treatment" in the era of increasing prevalence of antimicrobial resistance.

Entities:  

Keywords:  Bacterial eradication; Concomitant therapy; Helicobacter pylori; Hybrid therapy; Standard therapy

Mesh:

Substances:

Year:  2014        PMID: 24914324      PMCID: PMC4024773          DOI: 10.3748/wjg.v20.i19.5654

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  56 in total

1.  Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.

Authors:  H G Park; M K Jung; J T Jung; J G Kwon; E Y Kim; H E Seo; J H Lee; C H Yang; E S Kim; K B Cho; K S Park; S H Lee; K O Kim; S W Jeon
Journal:  Aliment Pharmacol Ther       Date:  2011-11-08       Impact factor: 8.171

2.  Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report.

Authors:  P Malfertheiner; F Megraud; C O'Morain; F Bazzoli; E El-Omar; D Graham; R Hunt; T Rokkas; N Vakil; E J Kuipers
Journal:  Gut       Date:  2006-12-14       Impact factor: 23.059

3.  The efficacy of two-week quadruple first-line therapy with bismuth, lansoprazole, amoxicillin, clarithromycin on Helicobacter pylori eradication: a prospective study.

Authors:  Bilal Ergül; Zeynal Doğan; Murat Sarikaya; Levent Filik
Journal:  Helicobacter       Date:  2013-09-09       Impact factor: 5.753

4.  Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

Authors:  J M Lee; N P Breslin; D K Hyde; M J Buckley; C A O'Morain
Journal:  Aliment Pharmacol Ther       Date:  1999-04       Impact factor: 8.171

5.  A randomized comparison of quadruple and triple therapies for Helicobacter pylori eradication: The QUADRATE Study.

Authors:  Peter H Katelaris; Geoffrey M Forbes; Nicholas J Talley; Brendan Crotty
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

6.  Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.

Authors:  J P Gisbert; J-L Gisbert; S Marcos; I Jimenez-Alonso; R Moreno-Otero; J M Pajares
Journal:  Aliment Pharmacol Ther       Date:  2007-11-12       Impact factor: 8.171

7.  High eradication rates of Helicobacter pylori with a new sequential treatment.

Authors:  A Zullo; D Vaira; N Vakil; C Hassan; L Gatta; C Ricci; V De Francesco; M Menegatti; A Tampieri; F Perna; V Rinaldi; F Perri; C Papadìa; F Fornari; S Pilati; L S Mete; A Merla; R Potì; G Marinone; A Savioli; S M A Campo; D Faleo; E Ierardi; M Miglioli; S Morini
Journal:  Aliment Pharmacol Ther       Date:  2003-03-01       Impact factor: 8.171

8.  A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori.

Authors:  M B Fennerty; T O Kovacs; R Krause; M Haber; A Weissfeld; N Siepman; P Rose
Journal:  Arch Intern Med       Date:  1998 Aug 10-24

Review 9.  Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.

Authors:  Jay Luther; Peter D R Higgins; Phillip S Schoenfeld; Paul Moayyedi; Nimish Vakil; William D Chey
Journal:  Am J Gastroenterol       Date:  2009-09-15       Impact factor: 10.864

10.  Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.

Authors:  Adrian G McNicholl; Alicia C Marin; Javier Molina-Infante; Manuel Castro; Jesús Barrio; Julio Ducons; Xavier Calvet; Cristobal de la Coba; Miguel Montoro; Felipe Bory; Angeles Perez-Aisa; Montserrat Forné; Javier P Gisbert
Journal:  Gut       Date:  2013-05-11       Impact factor: 23.059

View more
  7 in total

1.  A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China.

Authors:  Yan Zhou; Zishao Zhong; Shengjuan Hu; Jing Wang; Yanhong Deng; Ximei Li; Xianmei Chen; Xue Li; Yuanyuan Tang; Xiaofei Li; Qian Hao; Jun Liu; Tian Sang; Yang Bo; Feihu Bai
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

2.  Molecular and Proteomic Analysis of Levofloxacin and Metronidazole Resistant Helicobacter pylori.

Authors:  Aimi Hanafi; Woon Ching Lee; Mun Fai Loke; Xinsheng Teh; Ain Shaari; Mojdeh Dinarvand; Philippe Lehours; Francis Mégraud; Alex Hwong Ruey Leow; Jamuna Vadivelu; Khean Lee Goh
Journal:  Front Microbiol       Date:  2016-12-15       Impact factor: 5.640

3.  Online registry for nationwide database of Helicobacter pylori eradication in Korea: Correlation of antibiotic use density with eradication success.

Authors:  Beom Jin Kim; Chang-Hun Yang; Hyun Joo Song; Seong Woo Jeon; Gwang Ha Kim; Hyun-Soo Kim; Tae Ho Kim; Ki-Nam Shim; Il-Kwun Chung; Moo In Park; Il Ju Choi; Ji Hyun Kim; Byung-Wook Kim; Gwang Ho Baik; Sok Won Han; Hyang Eun Seo; Woon Tae Jung; Jung Hwan Oh; Sang Gyun Kim; Jun Haeng Lee; Sue K Park; Byung-Joo Park; Bo Ram Yang; Joongyub Lee; Jae G Kim
Journal:  Helicobacter       Date:  2019-08-01       Impact factor: 5.753

4.  Biofilm Formation and Antibiotic Resistance Phenotype of Helicobacter pylori Clinical Isolates.

Authors:  Kartika Afrida Fauzia; Muhammad Miftahussurur; Ari Fahrial Syam; Langgeng Agung Waskito; Dalla Doohan; Yudith Annisa Ayu Rezkitha; Takashi Matsumoto; Vo Phuoc Tuan; Junko Akada; Hideo Yonezawa; Shigeru Kamiya; Yoshio Yamaoka
Journal:  Toxins (Basel)       Date:  2020-07-24       Impact factor: 4.546

5.  Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México.

Authors:  Margarita Camorlinga-Ponce; Alejandro Gómez-Delgado; Emmanuel Aguilar-Zamora; Roberto C Torres; Silvia Giono-Cerezo; Antonio Escobar-Ogaz; Javier Torres
Journal:  Front Cell Infect Microbiol       Date:  2021-02-11       Impact factor: 5.293

6.  A Comparative Study of Efficacy and Safety of Two Eradication Regimens for Helicobacter pylori Infection.

Authors:  Carmen Monica Preda; Doina Proca; Irina Sandra; Larisa Elena Fulger; Boroka Claudia Horeanga; Mircea Manuc; Teodora Manuc; Catalin Andrei Dutei; Mihaela Barbu; Letitia Tugui; Adriana-Corina Andrei; Bogdan Ionut Slavulete; Mircea Diculescu
Journal:  Maedica (Bucur)       Date:  2017-09

7.  Identification of low abundance microbiome in clinical samples using whole genome sequencing.

Authors:  Chao Zhang; Kyle Cleveland; Felice Schnoll-Sussman; Bridget McClure; Michelle Bigg; Prashant Thakkar; Nikolaus Schultz; Manish A Shah; Doron Betel
Journal:  Genome Biol       Date:  2015-11-27       Impact factor: 13.583

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.